Femme et Homme
- | Pays : -
- | Organes : -
- | Spécialités : -
Extrait
To assess efficacy (objective response rate, ORR) of adding panitumumab to FOLFOXIRI in patients with newly diagnosed metastatic colorectal cancer expressing wild-type RAS Cohort I) Definitively unresectable metastatic disease, with a focus on symptomatic metastatic disease and/or large tumor load, or Cohort II) With chance of secondary resection with curative intent according to recent S3 guidelines of the German Cancer Society. The ORR will be compared to expectations derived from historical data, which are verified by a randomised control group without the antibody.
Critère d'inclusion
- non-resectable metastatic colorectal cancer